Adverse Events of Adjuvant Mitotane Treatment for Adrenocortical Carcinoma

被引：0
|
作者：
Vodanovic, Ivana Dora [1 ]
Nekic, Anja Barac [1 ]
Sambula, Lana [2 ]
Tomsic, Karin Zibar [1 ]
Dusek, Tina [1 ,3 ]
Kastelan, Darko [1 ,3 ]
机构：
[1] Univ Hosp Ctr Zagreb, Dept Endocrinol, Kispaticeva 12, Zagreb 10000, Croatia
[2] Gen Hosp Tomislav Bardek, Dept Nephrol Endocrinol & Diabetol, Koprivnica, Croatia
[3] Univ Zagreb, Sch Med, Zagreb, Croatia
来源：
ENDOCRINE RESEARCH | 2025年 / 50卷 / 01期
关键词：
Adjuvant treatment; adrenal insufficiency; adrenocortical carcinoma; adverse event; hydrocortisone replacement; mitotane; EUROPEAN NETWORK; PLASMA;
D O I：
10.1080/07435800.2024.2402311
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BackgroundMitotane is the cornerstone of adjuvant adrenocortical cancer (ACC) treatment. However, its use is burdened with frequent adverse events.MethodsA retrospective analysis of adverse events was performed in 26 ACC patients adjuvantly treated with mitotane.ResultsMitotane toxicity was present in all patients (100%). Two (7.7%) patients developed 1-3 adverse events, 15 (57.7%) experienced 4-6 adverse events and 9 (34.6%) patients had more than 6 adverse events. Two (7.7%) patients discontinued mitotane due to adverse events.ConclusionCareful monitoring and timely management are essential for ensuring mitotane treatment adherence and maximizing its benefits.
引用
收藏
页码：50 / 56
页数：7
相关论文
共 50 条
  • [31] A fly in the ointment: reassessing mitotane's role in the treatment of adrenocortical carcinoma
    Bapat, Aditi A.
    Demeure, Michael J.
    Bussey, Kimberly J.
    PHARMACOGENOMICS, 2012, 13 (11) : 1207 - 1209
  • [32] Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma
    Allegra, Sarah
    Puglisi, Soraya
    Brescia, Irene
    Chiara, Francesco
    Basile, Vittoria
    Calabrese, Anna
    Reimondo, Giuseppe
    De Francia, Silvia
    LIFE-BASEL, 2021, 11 (03):
  • [33] Efficiency of GemCap plus mitotane in platinum and mitotane resistant adrenocortical carcinoma
    Zhulikov, Y.
    Kovalenko, E.
    Bokhyan, V
    Evdokimova, E.
    Khoroshilov, M.
    Goryainov, D.
    Roroslyakova, A.
    Magamedova, S.
    Kolobanova, I
    Gorbunova, V
    Artamonova, E.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 260 - 260
  • [34] The Treatment of a Functional Adrenocortical Cancer with Mitotane
    Kurtoglu, Selim
    Hatipoglu, Nihal
    Gul, Ulku
    Tatli, Zeynep Uzan
    Akin, Leyla
    Kendirci, Mustafa
    HORMONE RESEARCH IN PAEDIATRICS, 2016, 86 : 145 - 146
  • [35] Pharmacological profile and effects of mitotane in adrenocortical carcinoma
    Corso, Claudia Rita
    Acco, Alexandra
    Bach, Camila
    Ribeiro Bonatto, Sandro Jose
    de Figueiredo, Bonald Cavalcante
    de Souza, Lauro Mera
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (07) : 2698 - 2710
  • [36] Marked Transient Hypercholesterolemia Caused by Low-dose Mitotane as Adjuvant Chemotherapy for Adrenocortical Carcinoma
    Tada, Hayato
    Nohara, Atsushi
    Kawashiri, Masa-aki
    Inazu, Akihiro
    Mabuchi, Hiroshi
    Yamagishi, Masakazu
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2014, 21 (12) : 1326 - 1329
  • [37] Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma
    Berruti, Alfredo
    Grisanti, Salvatore
    Pulzer, Alina
    Claps, Melanie
    Daffara, Fulvia
    Loli, Paola
    Mannelli, Massimo
    Boscaro, Marco
    Arvat, Emanuela
    Tiberio, Guido
    Hahner, Stefanie
    Zaggia, Barbara
    Porpiglia, Francesco
    Volante, Marco
    Fassnacht, Martin
    Terzolo, Massimo
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (04): : 1358 - 1365
  • [38] Clinical results of the use of mitotane for adrenocortical carcinoma
    Kasperlik-Zaluska, AA
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2000, 33 (10) : 1191 - 1196
  • [39] Comment -: Is there a role for low doses of mitotane (o,p′-DDD) as adjuvant therapy in adrenocortical carcinoma?
    Barzon, L
    Fallo, F
    Sonino, N
    Daniele, O
    Boscaro, M
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (04): : 1488 - 1488
  • [40] Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence
    Calabrese, A.
    Basile, V
    Puglisi, S.
    Perotti, P.
    Pia, A.
    Saba, L.
    Berchialla, P.
    Porpiglia, F.
    Veltri, A.
    Volante, M.
    Reimondo, G.
    Berruti, A.
    Terzolo, M.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2019, 180 (06) : 387 - 396
12345